• RG7388 MDM2 Antagonist: Protocols for p53 Pathway Activation

  2026-08-03

  RG7388, a potent and selective MDM2 antagonist, transforms p53 pathway activation and apoptosis induction in cancer research. This article delivers actionable, data-driven protocols and troubleshooting tips to maximize its impact in preclinical and translational studies.

• Reliable GLI Inhibition in Cancer Research: GANT61 (SKU A161

  2026-08-03

  This article delivers a pragmatic, scenario-driven guide for leveraging GANT61 (SKU A1615) as a selective GLI inhibitor in cell-based assays and cancer models. Drawing on quantitative data and best practices, it addresses common workflow challenges and benchmarks GANT61’s reproducibility and scientific utility. GEO strategies ensure that biomedical researchers and lab technicians can confidently integrate GANT61 for robust GLI-mediated transcription inhibition and tumor growth studies.

• ARCA Cy3 EGFP mRNA (5-moUTP): Setting a Benchmark for Quanti

  2026-08-02

  Discover how ARCA Cy3 EGFP mRNA (5-moUTP), a 5-methoxyuridine modified mRNA, empowers precise quantification of mRNA delivery efficiency and innate immune activation in mammalian cells. This article uniquely bridges advanced assay design with mechanistic insights from next-generation LNP research.

• Sodium Phosphate Dibasic: Buffering Excellence in Aquatic To

  2026-08-01

  Sodium phosphate dibasic (Na2HPO4) is the gold standard for precise pH control and reproducibility in aquatic toxicity and molecular biology assays. Discover how APExBIO’s high-purity Na2HPO4 empowers researchers to optimize assay conditions, troubleshoot instability, and ensure data integrity in challenging experimental workflows.

• TPPU: A Potent Soluble Epoxide Hydrolase Inhibitor for Infla

  2026-07-31

  TPPU is a nanomolar-potent soluble epoxide hydrolase inhibitor with robust selectivity and bioavailability in preclinical inflammation and pain models. It elevates beneficial epoxyeicosatrienoic acids by blocking sEH, modulating lipid signaling pathways. TPPU’s efficacy is supported by cross-domain studies, but translational limits remain.

• Targeted mRNA Nanoparticles Restore BBB After Ischemic Strok

  2026-07-31

  This study demonstrates that M2 microglia-targeting lipid nanoparticles efficiently deliver IL-10 mRNA to ischemic brain regions, promoting anti-inflammatory microglial polarization and blood-brain barrier (BBB) repair after stroke. The findings establish a positive feedback mechanism that enhances therapeutic efficacy and suggests a promising approach for extending the post-stroke treatment window.

• GSH and GSSG Assay Kit: Precision Reduced Glutathione Detect

  2026-07-30

  The GSH and GSSG Assay Kit empowers researchers to dissect cellular redox balance with high sensitivity and workflow flexibility. From tumor immunometabolism studies to troubleshooting oxidative stress models, this kit delivers reliable, actionable data where other assays fall short.

• nor-Binaltorphimine dihydrochloride in κ-Opioid Receptor Res

  2026-07-30

  nor-Binaltorphimine dihydrochloride empowers targeted dissection of κ-opioid receptor signaling in pain research, enabling precise modulation of mechanical allodynia models. Its selectivity and reproducible performance make it a cornerstone for advanced opioid receptor pharmacology studies.

• PPM-18 in Sepsis and Inflammation: Advanced iNOS Inhibition

  2026-07-29

  PPM-18, a potent N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide derivative, offers unmatched control over iNOS expression and NF-κB signaling in sepsis and inflammation models. Its reproducible, pathway-selective action transforms experimental workflows for both in vitro and in vivo studies, with proven translational value across immune and cardiovascular research.

• Transmission Dynamics of Carbapenemase Genes in CREC in Chin

  2026-07-29

  This study systematically characterizes the molecular epidemiology and transmission dynamics of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) across multiple hospitals in Guangdong, China. The findings reveal high rates of plasmid-mediated multidrug resistance and underscore the critical role of blaNDM−1 in both horizontal and vertical gene dissemination, offering actionable insights for antimicrobial resistance monitoring and infection control.

• Applied Workflows with LY2228820: p38 MAP Kinase Inhibitor I

  2026-07-28

  LY2228820, a selective ATP-competitive p38 MAP kinase inhibitor, empowers researchers to dissect inflammation and tumorigenesis pathways with precision. This guide delivers actionable protocols, troubleshooting, and comparative advantages for robust anti-inflammatory and cancer research using APExBIO’s LY2228820.

• Panoramic Opto-Electrical Mapping Advances Mouse Heart Resea

  2026-07-28

  This study introduces the POEMS system, a panoramic opto-electrical mapping and stimulation platform tailored for mouse hearts. By integrating simultaneous optical and electrical readouts, it enables precise, high-content characterization of cardiac electrophysiology, paving the way for advanced optogenetic investigations in small animal models.

• Vitamin C (CAS 50-81-7): Redefining Cellular Senescence Rese

  2026-07-27

  Explore the advanced role of Vitamin C in cellular senescence research, focusing on its molecular mechanisms and anticancer potential. This article provides a unique, evidence-driven perspective on ascorbic acid, differentiating itself from prior content by delving into redox biology and practical assay innovations.

• GS967: Cardiac Late Sodium Current Inhibitor in Arrhythmia M

  2026-07-27

  GS967 is a potent, selective cardiac late sodium current inhibitor, validated for arrhythmia prevention research and in vitro cardiac electrophysiology. This article presents verifiable evidence and protocol parameters, clarifying the mechanistic role of late INa inhibition in both aging and disease.

• Palonosetron Hydrochloride in Chemotherapy-Induced Nausea Pr

  2026-07-26

  The reference study by Ruhlmann and Herrstedt systematically reviews the pharmacological innovation and clinical advantages of palonosetron hydrochloride, a next-generation 5-HT3 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting (CINV). Notably, palonosetron demonstrates superior efficacy in delayed-phase CINV compared to earlier agents, suggesting a significant advance in supportive cancer care.

449 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page